TP53 and B-cell chronic lymphocytic leukemia: Rates of CR (56% vs. 56%) and PB uMRD (81% vs. 75%) were similar for patients with CLL with (n = 27) or without (n = 129) TP53 aberrancy, although 24-month PFS rates appeared slightly inferior (84% [95% CI 63–94] vs. 96% [95% CI 91–98]) [52].